Clinical progress of Decitabine
YANG Tongjiang
CHEN Yancheng
XIE Lili
SHAN Yanqiang
Abstract：Decitabine is a nucleoside metabolic inhibitor indicated for treatment of patients with myelodysplastic syndromes (MDS).In September 2012,the European Medicines Agency approved as a treatment for acute myelogenous leukemia.The advancement of Decitabine in current clinic researches are reviewed in this article.
Keywords：DecitabineAnticancerClinical progress
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 302-304 )